Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis
Author:
Funder
Albireo Pharma, Inc.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12325-022-02262-7.pdf
Reference21 articles.
1. Data on file. Boston: Albireo Pharma, Inc; 2022.
2. Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 2020;40(8):1812–22. https://doi.org/10.1111/liv.14553.
3. Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020;14(5):677–89. https://doi.org/10.1007/s12072-020-10070-w.
4. Gunaydin M, Bozkurter Cil AT. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepatic Med. 2018;10:95–104. https://doi.org/10.2147/hmer.S137209.
5. Thebaut A, Debray D, Gonzales E. An update on the physiopathology and therapeutic management of cholestatic pruritus in children. Clin Res Hepatol Gastroenterol. 2018;42(2):103–9. https://doi.org/10.1016/j.clinre.2017.08.007.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial;The Lancet Gastroenterology & Hepatology;2024-07
2. Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA;Current Drug Research Reviews;2024-03
3. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis;JHEP Reports;2024-01
4. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis;JHEP Reports;2023-08
5. Case Report: Add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis;Frontiers in Pediatrics;2023-02-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3